Studies analyzing expression and functional impact of E2F2 in these tumor types are underway, which will provide insight into the feasibility of targeting E2F2 to sensitize cancer cells to Fas/FasL-mediated apoptosis. The gene discussed is FAS; the disease is neoplasm.